A previously developed and verified probenecid PBPK model [21], incorporating endogenous biomarker‐informed in vivo OAT1/3 Ki obtained from PopPK modeling [15] of PDA clinical data [19], was applied to predict the DDI with adefovir. Here, SLC22A6 is linked to Patent ductus arteriosus.